Nikhil Khushalani

Nikhil Khushalani

Oncology
10920 McKinley Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

Journal: JAMA dermatology
Published: July 08, 2026

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Journal: JCO oncology practice
Published: June 23, 2026

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Journal: Frontiers in immunology
Published: March 23, 2026

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Journal: Med (New York, N.Y.)
Published: March 17, 2026

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Journal: Journal of neuro-oncology
Published: January 29, 2026

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers
Published: December 29, 2025

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Journal: Journal for immunotherapy of cancer
Published: December 16, 2025

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

Journal: Annals of surgical oncology
Published: December 08, 2025

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Journal: Cancers
Published: November 27, 2025

Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

Journal: The New England journal of medicine
Published: October 22, 2025
Showing 1-12 of 144

Last Updated: 09/26/2026